Retatrutide CAS：2381089-83-2 Motif Biotech

Retatrutide is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.

Name Retatrutide	Molecular structural formula
Purity ≥98%
CAS Number 2381089-83-2
Formula C221H342N46O68
MW 4731.33
Pharmacology Retatrutide is a 39 amino acid single peptide with triple agonist activity at the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). The backbone is conjugated to a C20 fatty diacid moiety at position 17. Retatrutide has a Glucose-dependent insulinotropic polypeptide (GIP) peptide backbone, which then contains three non-coded amino acids. Aib2 (α-amino isobutyric acid) residues at positions 2 and 20 provide stability against Dipeptidyl Peptidase 4 (DPP4) cleavage and contribute to GIP activity. αMeL13 (α-methyl-L-leucine)at position 20 also contributes to GIP and glucagon activity. Retatrutide can be used for the research of obesity obesity, diabetes, and fatty liver disease. It is a works in three ways: stimulating insulin release, suppressing appetite, and promoting fat breakdown.
Indications Obesity；Diabetes
Contraindications Patients with a history or family history of medullary thyroid cancer Multiple endocrine neoplasia type 2, etc.
Route of administration subcutaneous injection
Target GCGR；GLP Receptor
Sequence Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Sequence Shortening Y-{Aib}-QGTFTSDYSI-{α-Me-Leu}-LDK-{diacid-C20-gamma-Glu-(PEG2)-Lys}AQ-{Aib}-AFIEYLLEGGPSSGAPPPS-NH2
InChIKey PIHZSFXNGVXGER-QQQDAUCCSA-N
Solubility in DMSO 50 mg/mL
Solubility in water 20 mg/mL
References [1]. Tamer Coskun, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.